Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04612062 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of CEE321 in Adult Subjects
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04612062 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT04612062, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis
Interventions
- DRUG CEE321
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-02-27 |
| Est. Completion | 2021-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04612062
The ClinicalTrials.gov registry entry for NCT04612062 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CEE321 is the first listed.
NCT04612062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04612062 about?
NCT04612062 is a clinical study titled "A First-in-Human Study of CEE321 in Adult Subjects". Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis
What is the current status of trial NCT04612062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2020-02-27. Estimated completion is 2021-05-16.
What interventions are being tested in trial NCT04612062?
The interventions under investigation include: CEE321 (DRUG).
Who is sponsoring clinical trial NCT04612062?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.